9. Abeona Therapeutics Inc. (NASDAQ:ABEO)
Abeona Therapeutics Inc. is no longer just a development-stage biotech story—it is actively transitioning into a commercialization-driven company, and that changes everything about how the market values it. In the context of biotech growth stocks, this shift from “pipeline potential” to “revenue execution” is often where multiple expansion begins. Abeona’s focus on gene therapy, particularly in rare diseases, places it in one of the most attractive and capital-intensive segments of the healthcare sector.
Recent developments have reinforced this narrative. The company has achieved regulatory progress that positions it closer to sustained revenue generation, and management has been clear about its priorities moving forward. In its latest communications, Abeona emphasized its strategy to “execute a disciplined commercial launch while expanding patient access globally,” signaling that the company is now operating with a revenue-first mindset. Historically, micro-cap biotech companies that successfully cross into commercialization often experience a significant re-rating, especially when early adoption validates the science. ABEO is now firmly in that transition phase, making it one of the more compelling names among biotech stocks to watch.
Click next to see the following stock...
